gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · PRMEHealthcareBiotechnology

Prime Medicine, Inc. Common Stock (PRME)

$4.97+9.23%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$4.97▲ 15.58% in range
Nov 4, 2025Low $2.70 · High $5.36Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Prime Medicine closed at $4.97 on Nov 4, up 9.23%, 7.3% below its 52-week closing high. Volume of 4.4M shares was 0.73× its 20-day average (below normal).

Split-adjusted performance: +42.0% over one month, +45.7% over six months, +9.0% over one year.

In the quarter ended Jun 30, 2026, revenue was $1.15M, up 3.5% from a year earlier, with a net margin of -3649.0%.

Short interest was 32.9M shares at the Oct 15 settlement, up 2.4% from the prior report (34.4% of float, 5.5 days to cover).

Market cap$901.4M181.4M shares
Revenue · quarter$1.2M+3.5% YoY
Diluted EPS$-0.24—
P/E · TTM—P/S 221.3×
Net margin-3,649.0%Gross 100.0%
Dividend yieldNone$0.8 last paid
52-week range2.70 – 5.36−7.3% from high
Volume4.4M0.73× 20-day avg
Volatility · 60d112.8%Annualised
Short % of float34.4%5.5 days to cover
Net cash$95.1MCash $95.1M
Next earnings—Not scheduled
Split-adjusted performance
1W −7.3%1M +42.0%3M +68.5%6M +45.7%YTD +43.2%1Y +9.0%3Y −14.6%5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum89
Revenue growth44
Net margin16
Value (low P/E)—
Size70

Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.

Short interest

Details →
Shares short32.9M+2.4% vs prior
Days to cover5.5Settled Oct 15
% of float34.4%
Short vol. 10d52.8%of daily volume

Closest peers by size in Biotechnology

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
PRMEPrime Medicine$4.97+9.23%+45.7%+3.5%−3649.0%—$901.4M
MGTXMeiraGTx Holdings$9.42−1.05%−4.8%+8608.6%50.0%11.5$904.7MCompare
GLUEMonte Rosa Therapeutics$10.82+3.94%−46.9%−61.3%−483.9%—$923.1MCompare
ODTXOdyssey Therapeutics$19.50−9.60%————$937.1MCompare
CGEMCullinan Therapeutics$12.49−20.70%−16.7%———$803.8MCompare
DNAGinkgo Bioworks Holdings$11.65+8.27%+15.6%−48.5%−231.7%—$784.5MCompare
SANASana Biotechnology$2.56+4.92%−29.7%———$766.4MCompare
ATTOAttovia Therapeutics$15.60+2.16%————$712.2MCompare
SLDBSolid Biosciences$6.52+3.82%−9.4%———$699.1MCompare

News about Prime Medicine

All news →
Prime Medicine, Inc. (PRME) Surges 23.2%: Is This an Indication of Further Gains?Zacks Investment Research · Oct 29, 2026NeutralPrime Medicine Stock Rallies Nearly 26% in a Month: Here's WhyZacks Investment Research · Oct 12, 2026▲ PositivePrime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson DiseaseGlobeNewswire Inc. · Oct 5, 2026▲ PositiveOcular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool · Jun 15, 2026NeutralPrime Medicine to Participate in Upcoming Investor ConferencesGlobeNewswire Inc. · Feb 25, 2026Neutral

Quick answers

What does Prime Medicine do?
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models.
What is PRME's market cap?
$901.44M, based on the Nov 4 close of $4.97.
Does Prime Medicine pay a dividend?
No regular cash dividend has been paid in the last year.
How much of PRME is sold short?
32.9M shares, 34.4% of float, as of Oct 15, 2026.
What sector is PRME in?
Healthcare, in the Biotechnology industry.

About Prime Medicine

Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.

HQ: Cambridge, MA146 employeesListed Oct 20, 2022primemedicine.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology